Biotechnology
Key highlights
- India’s bioeconomy reached approximately ₹1,953,000 Cr in CY25, up 18% YoY, supported by BioIndustrial, BioPharma, BioServices and BioAgri activity.
- Anthem Biosciences’ Q1 FY27 operating revenue fell 22.6% YoY to ₹418.2 Cr, but its EBITDA margin expanded 153 bps YoY to 39.6%, demonstrating strong cost and process economics.
- Advanced Enzyme Technologies’ Q1 FY27 operating revenue grew 2% YoY to ₹189.8 Cr; an incremental ₹10.0 Cr transit-related reversal reduced reported growth from an underlying management estimate of roughly 8% YoY.
- The two companies address distinct biotechnology value pools: Anthem is primarily a global CRDMO and custom-manufacturing platform, while Advanced Enzyme is diversified across healthcare, nutrition, industrial enzymes and specialized manufacturing.
- Major medium-term triggers include Anthem’s late-stage pipeline, Unit 3 ramp-up, Unit 4 commissioning and semaglutide approval; for Advanced Enzyme, triggers include margin recovery, food enzymes, specialized manufacturing, biocatalysis and new R&D capacity.
- Regulatory delays, quarterly order timing, energy and input costs, customer inventory adjustment, commercialization risk and high capital intensity remain the principal earnings risks.
powered by IRIS
Unlock full access to this sectoral analysis with in-depth insights, comprehensive data, and exclusive reports.


